Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 851.95M | 752.84M | 585.88M | 464.68M | 358.43M |
Gross Profit | 537.66M | 438.07M | 332.49M | 275.75M | 234.41M |
EBITDA | 255.43M | 225.88M | 159.99M | 168.81M | 143.23M |
Net Income | 191.91M | 156.46M | 131.71M | 142.96M | 121.35M |
Balance Sheet | |||||
Total Assets | 2.26B | 2.03B | 1.83B | 1.62B | 1.42B |
Cash, Cash Equivalents and Short-Term Investments | 554.51M | 434.40M | 528.27M | 640.55M | 941.59M |
Total Debt | 243.69M | 94.78M | 48.83M | 13.40M | 1.73M |
Total Liabilities | 473.39M | 351.25M | 273.23M | 183.63M | 95.04M |
Stockholders Equity | 1.77B | 1.65B | 1.51B | 1.40B | 1.31B |
Cash Flow | |||||
Free Cash Flow | 59.80M | -53.05M | -62.75M | -205.07M | 7.92M |
Operating Cash Flow | 225.54M | 178.15M | 180.46M | 72.76M | 95.71M |
Investing Cash Flow | -187.31M | -283.81M | -316.18M | -268.08M | -221.87M |
Financing Cash Flow | 56.97M | 8.06M | 9.72M | -31.07M | -27.95M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
83 Outperform | €9.53B | 15.05 | 18.36% | 23.34% | 7.13% | 13.39% | |
74 Outperform | €4.03B | 9.96 | 15.04% | 4.27% | 6.05% | 1.32% | |
72 Outperform | €2.01B | 12.37 | 3.72% | 120.35% | 11.84% | -2.22% | |
68 Neutral | HK$17.83B | 33.35 | 28.81% | 0.95% | 14.99% | 31.70% | |
67 Neutral | HK$4.40B | 19.76 | 11.24% | 1.20% | 11.23% | 20.39% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
45 Neutral | €95.80M | ― | ― | -0.28% | -713.33% |
Shanghai INT Medical Instruments Co., Ltd. has released a supplemental announcement detailing the emoluments paid to its supervisors from 2019 to 2024. The announcement clarifies that the emoluments were paid in their capacity as employees of the group, not as supervisors, and does not alter any other information in the company’s annual reports.
The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.
Shanghai INT Medical Instruments Co., Ltd., a company incorporated in China, held its annual general meeting for 2024 on May 23, 2025. The meeting, chaired by Dr. Liang Dongke, resulted in the approval of all resolutions, including the re-election and appointment of directors and supervisors, and the election of the chairman for the fourth session of the board and supervisory committee. The unanimous approval of the company’s reports and financial statements reflects strong shareholder support and positions the company for continued stability and governance.
The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.
Shanghai Kindly Medical Instruments Co., Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and decision-making processes, which could influence stakeholders’ perspectives on the company’s future operations.
The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.
Shanghai Kindly Medical Instruments Co., Ltd., a company incorporated in the People’s Republic of China, has entered into a Formal Acquisition Agreement to acquire a controlling stake in a target company. The acquisition involves purchasing 81.83% equity interest in the target company for approximately RMB512.84 million, with Shanghai Kindly Medical Instruments acquiring a 51.70% controlling stake. This transaction will result in the target company becoming a non-wholly owned subsidiary, and further capital injection is planned. The acquisition is classified as a discloseable transaction under the Listing Rules, requiring reporting and announcement.
The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.
Shanghai Kindly Medical Instruments Co., Ltd. has announced its upcoming annual general meeting scheduled for May 23, 2025. The meeting will address several resolutions, including the approval of the 2024 financial reports, re-elections of board members, and the appointment of auditors. These decisions are crucial for maintaining the company’s governance and operational continuity.